Hepsera

Hepsera is a brand name of adefovir, approved by the FDA in the following formulation(s):

HEPSERA (adefovir dipivoxil - tablet; oral)

• 
  Manufacturer: GILEAD
  
  Approval date: September 20, 2002
  
  Strength(s): 10MG ^[RLD]

Has a generic version of Hepsera been approved?

No. There is currently no therapeutically equivalent version of Hepsera available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Hepsera. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Prodrugs of phosphonates
  Patent 5,663,159
  Issued: September 2, 1997
  Inventor(s): Starrett, Jr.; John E. & Mansuri; Muzammil M. & Martin; John C. & Tortolani; David R. & Bronson; Joanne J.
  Assignee(s): Institute of Organic Chemistry and Biochemistry of the Academy of
  Rega Stichting v.z.w.
  There are disclosed novel oral prodrugs of phosphonate nucleotide analogs which are hydrolyzable under physiological conditions to yield compounds which are useful as antiviral agents, especially as agents effective against RNA and DNA viruses. They may also find use as antitumor agents.
  
  Patent expiration dates:
  
  
  • September 2, 2014
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Nucleotide analog compositions
  Patent 6,451,340
  Issued: September 17, 2002
  Inventor(s): Murty N.; Arimilli & Daphne E.; Kelly & Thomas T. K.; Lee & Lawrence V.; Manes & John D.; Munger, Jr. & Ernest J.; Prisbe & Lisa M.; Schultze
  Assignee(s): Gilead Sciences, Inc.
  The invention provides crystalline forms of adefovir dipivoxil and methods to prepare the crystals. The compositions and methods of the present invention have desirable properties for large scale synthesis of crystalline adefovir dipivoxil or for its formulation into therapeutic dosages. Invention compositions include an anhydrous crystal form of adefovir dipivoxil.
  
  Patent expiration dates:
  
  
  • July 23, 2018
    
    ✓ 
    Patent use: THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • December 19, 2010 - NEW PATIENT POPULATION
  
  

See also...

• Hepsera Consumer Information (Wolters Kluwer)
• Hepsera Consumer Information (Cerner Multum)
• Hepsera AHFS DI Monographs (ASHP)
• Adefovir Consumer Information (Wolters Kluwer)
• Adefovir Consumer Information (Cerner Multum)
• Adefovir Advanced Consumer Information (Micromedex)
• Adefovir Dipivoxil AHFS DI Monographs (ASHP)